BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37256945)

  • 1. Gain-of-function mutations in the catalytic domain of
    Zhang J; Yang T; Han M; Wang X; Yang W; Guo N; Ren Y; Cui W; Li S; Zhao Y; Zhai X; Jia L; Yang J; Wu C; Wang L
    Sci Adv; 2023 Jun; 9(22):eadc9273. PubMed ID: 37256945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
    Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
    Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DOT1L promotes cell proliferation and invasion by epigenetically regulating STAT5B in renal cell carcinoma.
    Hou Y; Huang S; Liu J; Wang L; Yuan Y; Liu H; Weng X; Chen Z; Hu J; Liu X
    Am J Cancer Res; 2023; 13(1):276-292. PubMed ID: 36777512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
    Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
    Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methyltransferase Dot1l preferentially promotes innate IL-6 and IFN-β production by mediating H3K79me2/3 methylation in macrophages.
    Chen X; Liu X; Zhang Y; Huai W; Zhou Q; Xu S; Chen X; Li N; Cao X
    Cell Mol Immunol; 2020 Jan; 17(1):76-84. PubMed ID: 30275539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOT1L Epigenetically Regulates Autophagy and Mitochondria Fusion in Cell Lines of Renal Cancer.
    Hou Y; Liu J; Huang S; Wang L; Hu J; Liu X
    Technol Cancer Res Treat; 2023; 22():15330338231167249. PubMed ID: 37365941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of DOT1L in the proliferation and prognosis of gastric cancer.
    Song Z; Wei Z; Wang Q; Zhang X; Tao X; Wu N; Liu X; Qian J
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31939604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.
    Yu W; Chory EJ; Wernimont AK; Tempel W; Scopton A; Federation A; Marineau JJ; Qi J; Barsyte-Lovejoy D; Yi J; Marcellus R; Iacob RE; Engen JR; Griffin C; Aman A; Wienholds E; Li F; Pineda J; Estiu G; Shatseva T; Hajian T; Al-Awar R; Dick JE; Vedadi M; Brown PJ; Arrowsmith CH; Bradner JE; Schapira M
    Nat Commun; 2012; 3():1288. PubMed ID: 23250418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone methyltransferase DOT1L is a new epigenetic regulator of pulmonary fibrosis.
    Yang D; Xu P; Su H; Zhong W; Xu J; Su Z; Liu X
    Cell Death Dis; 2022 Jan; 13(1):60. PubMed ID: 35039472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
    Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
    Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetically modulated FOXM1 suppresses dendritic cell maturation in pancreatic cancer and colon cancer.
    Zhou Z; Chen H; Xie R; Wang H; Li S; Xu Q; Xu N; Cheng Q; Qian Y; Huang R; Shao Z; Xiang M
    Mol Oncol; 2019 Apr; 13(4):873-893. PubMed ID: 30628173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nullifying epigenetic writer DOT1L attenuates neointimal hyperplasia.
    Huang Y; Urabe G; Zhang M; Li J; Ozer HG; Wang B; Kent KC; Guo LW
    Atherosclerosis; 2020 Sep; 308():22-31. PubMed ID: 32799103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epigenetic enzyme DOT1L orchestrates vascular smooth muscle cell-monocyte crosstalk and protects against atherosclerosis via the NF-κB pathway.
    Farina FM; Serio S; Hall IF; Zani S; Cassanmagnago GA; Climent M; Civilini E; Condorelli G; Quintavalle M; Elia L
    Eur Heart J; 2022 Nov; 43(43):4562-4576. PubMed ID: 35292818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
    Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
    Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer.
    Zhang K; Wang J; Yang L; Yuan YC; Tong TR; Wu J; Yun X; Bonner M; Pangeni R; Liu Z; Yuchi T; Kim JY; Raz DJ
    Mol Cancer; 2018 Oct; 17(1):153. PubMed ID: 30348169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway.
    Sun D; Wang W; Guo F; Pitter MR; Du W; Wei S; Grove S; Vatan L; Chen Y; Kryczek I; Fearon ER; Fang JY; Zou W
    Oncoimmunology; 2022; 11(1):2052640. PubMed ID: 35309733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of the DNA damage response and gene expression by the Dot1L histone methyltransferase and the 53Bp1 tumour suppressor.
    FitzGerald J; Moureau S; Drogaris P; O'Connell E; Abshiru N; Verreault A; Thibault P; Grenon M; Lowndes NF
    PLoS One; 2011 Feb; 6(2):e14714. PubMed ID: 21383990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchyme-specific loss of Dot1L histone methyltransferase leads to skeletal dysplasia phenotype in mice.
    Sutter PA; Karki S; Crawley I; Singh V; Bernt KM; Rowe DW; Crocker SJ; Bayarsaihan D; Guzzo RM
    Bone; 2021 Jan; 142():115677. PubMed ID: 33022452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
    Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
    Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L.
    Lv L; Li Q; Chen S; Zhang X; Tao X; Tang X; Wang S; Che G; Yu Y; He L
    Exp Cell Res; 2019 Dec; 385(1):111597. PubMed ID: 31525340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.